Navigation Links
New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
Date:10/31/2008

- Subanalyses from the Phase 3 SHARP and Asia-Pacific trials to be presented at 59th Annual Meeting of the American Association for the Study

of Liver Diseases -

WAYNE, N.J. and EMERYVILLE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that new Nexavar data will be presented at the upcoming 59th Annual Meeting of the American Association for the Study of Live Diseases (AASLD) demonstrating the clinical application of Nexavar(R) (sorafenib) tablets in multiple patient subsets with hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the only systemic treatment to demonstrate prolonged overall survival in unresectable HCC and is currently approved in more than 60 countries for the treatment of the disease.

Data will be presented evaluating specific patient subpopulations from the Phase 3 SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific trials. The trials enrolled 602 and 226 patients, respectively, with advanced, unresectable HCC who had not received prior systemic therapy. Patients in both studies were randomized to receive either Nexavar 400 mg twice daily or placebo. Data from both Phase 3 trials demonstrated that patients treated with Nexavar experienced a significant improvement in overall survival; 44% (HR=0.69; p-value=0.0006) in the SHARP trial and 47% (HR=0.68; p-value=0.014) in the Asia Pacific trial.

"The SHARP and Asia Pacific trials continue to increase our understanding and provide clinical confirmation of the efficacy, safety and clinical benefit of Nexavar in patients with liver cancer," said Mark Gelder, MD, vice president, Therapeutic Area Oncology
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
2. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
5. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
6. PA Game Commission: EHD Outbreak Update: Test Results Confirm EHD In Beaver County
7. Actavis Confirms its Patent Challenge of Kings Avinza(R)
8. Barr Confirms Patent Challenge of UROXATRAL(R)
9. Pennsylvania Game Commission Announces EHD Confirmed in Allegheny and Westmoreland Counties
10. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
11. Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 2Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 3Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8